Abrinica, Clyde .

HRN: 27-22-75  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/25/2025
CEFTAZIDIME 1GM (VIAL)
08/25/2025
08/31/2025
IV
400mg
Q8h
PCAP C
Checking Initial Appropriateness 
08/28/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/28/2025
09/03/2025
IV
800mg
Q6h
PCAP D
Checking Initial Appropriateness 
08/28/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/28/2025
09/03/2025
IV
40mg
Q8h
PCAP D
Checking Initial Appropriateness 
08/29/2025
AZITHROMYCIN 200MG/5ML, 15ML SUSPENSION (SUSP)
08/29/2025
09/05/2025
IV
1ml
Q 24
PCAP-C
Checking Initial Appropriateness 
09/08/2025
CLARITHROMYCIN 125MG/5ML, 60ML SUSPENSION (BOT)
09/08/2025
09/14/2025
ORAL
2.5ml
Q12H
PCAP D
Checking Initial Appropriateness 
09/16/2025
CEFUROXIME 750MG (VIAL)
09/16/2025
09/22/2025
IVT
250mg
Q8
Sepsis
Checking Initial Appropriateness 
10/16/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
10/16/2025
10/23/2025
IV
400mg
Q 6 Hours
HAP (VAP)
Waiting Final Action 
10/22/2025
CEFTRIAXONE 1G (VIAL)
10/22/2025
10/29/2025
IV
800 Mg
Q 24
HAP (VAP)
Waiting Final Action 
10/22/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
10/22/2025
10/29/2025
IV
100 Mg
Q 8 Hours
HAP (VAP)
Waiting Final Action 
10/22/2025
CEFTRIAXONE 1G (VIAL)
10/22/2025
10/29/2025
IV
800mg
Q24h
PCAP C
Waiting Final Action 
10/22/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
10/22/2025
10/29/2025
IV
100mg
Q8h
PCAP C
Waiting Final Action 
10/31/2025
CEFTRIAXONE 1G (VIAL)
10/31/2025
11/04/2025
IV
800mg
Q24h
PCAP
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: